This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Davis SL , Cardin DB , Shahda S , Lenz HJ , Dotan E , O'Neil BH , Kapoun AM , Stagg RJ , Berlin J , Messersmith WA , Cohen SJ
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
Investigational New Drugs. 2020 Jun;38(3) :821-830
PMID: 31338636 PMCID: PMC7211194 URL: https://www.ncbi.nlm.nih.gov/pubmed/31338636
AbstractVantictumab is a fully human monoclonal antibody that inhibits Wnt pathway signaling through binding FZD1, 2, 5, 7, and 8 receptors. This phase Ib study evaluated vantictumab in combination with nab-paclitaxel and gemcitabine in patients with untreated metastatic pancreatic adenocarcinoma. Patients received vantictumab at escalating doses in combination with standard dosing of nab-paclitaxel and gemcitabine according to a 3 + 3 design. A total of 31 patients were treated in 5 dosing cohorts. Fragility fractures attributed to vantictumab occurred in 2 patients in Cohort 2 (7 mg/kg every 2 weeks), and this maximum administered dose (MAD) on study was considered unsafe. The dosing schedule was revised to every 4 weeks for Cohorts 3 through 5, with additional bone safety parameters added. Sequential dosing of vantictumab followed by nab-paclitaxel and gemcitabine was also explored. No fragility fractures attributed to vantictumab occurred in these cohorts; pathologic fracture not attributed to vantictumab was documented in 2 patients. The study was ultimately terminated due to concerns around bone-related safety, and thus the maximum tolerated dose (MTD) of the combination was not determined. The MAD of vantictumab according to the revised dosing schedule was 5 mg/kg (n = 16).
NotesDavis, S. Lindsey Cardin, Dana B. Shahda, Safi Lenz, Heinz-Josef Dotan, Efrat O'Neil, Bert H. Kapoun, Ann M. Stagg, Robert J. Berlin, Jordan Messersmith, Wells A. Cohen, Steven J. Hopkins, Katie/0000-0001-7279-5322 1573-0646